Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

This study is testing a new type of immune cell therapy called dual-target CAR-NK cells — engineered natural killer cells that attack two targets on cancer cells at once — for people with small cell lung cancer (SCLC) that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed small cell lung cancer that has spread or is unresectable, and has returned or stopped responding after at least one round of chemotherapy (including a platinum-based drug) - You have at least one measurable tumor - Your overall health is good (ECOG 0–1) - Your heart, kidneys, liver, and blood counts meet required levels - You are willing to use contraception during and after the study **You may NOT be eligible if...** - Cancer has spread to your brain in an uncontrolled way - You previously received CAR-T, CAR-NK, or similar gene-modified cell therapy within 6 months - You had a bone marrow transplant within the past 6 months or have active graft-versus-host disease - You have an active uncontrolled infection (including HIV, active hepatitis B/C, or tuberculosis) - You have significant heart disease - You have an active autoimmune disease requiring high-dose steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.